Skip to content

MR new technology(3D enhancement+DWI) for assessing diagnosis efficiency about colorectal cancer liver metastases

DiagnoStic performance of colorectal Liver Metastases: A MUlticenter, randomized, ProspectivE compaRison of contraSt-enhanced MRI with beTween Gd-EOB-DTPA and Gd-DTPA in patients with colorectal canceR – SUPERSTAR

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDT-13003049
Enrollment
Unknown
Registered
2013-02-09
Start date
2013-02-02
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer liver metastases

Interventions

Gold Standard:
Index test:

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged>18 years; (2) Patient who has histologically confirmed colorectal cancer within one month; (3) The patients above who have suspected liver metastases through ultrasound and/or CT; (4) The patients should not received any treatments such as:surgery or intervention or radio frequency,etc before this experiment; (5) The patients are in routine calinical process and follow up or surgery may be needed.

Exclusion criteria

Exclusion criteria: (1) Patients who had used to participate this study already; (2) Patients who are hypersensitive to any component of the MRI contrast agent or patient who has the history of severe allergy or allergic athma or hyperthyroidism; (3) Pregnant or lactating women; (4) Patients with severe damage of liver function(ALT value is two times more than normal value); (5) Patients whose eGFR are<60 ml/min/1.73 m2; (6) Patients who have any contraindications to MRI or CE-MRI; (7) Patients with other conditions that can not complete the examination.

Design outcomes

Primary

MeasureTime frame
Sensitivity;Accuracy;

Secondary

MeasureTime frame
Diagnosis accuracy;

Countries

China

Contacts

Public ContactXiaoying Wang
cjr.wangxiaoying@vip.163.com+86 10 83572097

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026